Edgewood Oncology’s Post

BTX-A51 represents a novel, synergistic mechanism for breast cancer patients with GATA3 mutations. Thanks to the physicians and patients who are making this possible, and to our great team of consultants whose dedicated efforts have gotten us to this point!

Exciting news from Edgewood Oncology! We have reached a major milestone as the first two patients have been dosed in our Phase 2a trial of BTX-A51, aimed at treating genetically-defined breast cancer. This trial focuses on ER+/HER2- metastatic breast cancer, evaluating the preliminary effectiveness of BTX-A51 in patients with and without GATA3 mutations. This is a significant step forward for those facing limited treatment options and a challenging prognosis. Read the press release and learn more about the proposed role of BTX-A51 in this breast cancer sub-population at www.edgewoodoncology.com #biotech #oncology #breastcancer #precisionmedicine #BTXA51 #edgewoodoncology #clinicaltrials

We are pleased to announce the publication of new preclinical data from a study of BTX-A51 in human liposarcoma (LPS), conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School, and presented at the American Association of Cancer Research Annual Meeting 2024. The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1alpha and CDK9. Read the press release and learn more about Edgewood Oncology at www.edgewoodoncology.com #biotech #oncology #liposarcoma #precisionmedicine

Today we are excited to emerge from stealth with $20 Million in Series A funding backed by Alta Partners. Edgewood Oncology is a clinical stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. Enrollment is underway in a Phase 2a combination study in acute myeloid leukemia, and we expect to initiate a Phase 2 study in breast cancer patients with a genetically-defined profile in Q2 2024. Read the press release and learn more about Edgewood Oncology at www.edgewoodoncology.com. #biotech #oncology #breastcancer #leukemia #precisionmedicine